Can Zostum (Cefoperazone-Sulbactam) Be Used for Febrile UTI?
Yes, cefoperazone-sulbactam (Zostum) can be used for febrile urinary tract infections, particularly in complicated UTIs and when ESBL-producing organisms are suspected, though it is not listed as a first-line agent in major international guidelines.
Guideline-Based Recommendations
Current 2024 guidelines do not specifically list cefoperazone-sulbactam as a preferred empirical agent for febrile UTIs. For uncomplicated pyelonephritis requiring hospitalization, the European Association of Urology recommends fluoroquinolones, aminoglycosides (with or without ampicillin), or extended-spectrum cephalosporins/penicillins as first-line intravenous therapy 1. For complicated UTIs with systemic symptoms (which includes fever), guidelines recommend amoxicillin plus aminoglycoside, second-generation cephalosporin plus aminoglycoside, or intravenous third-generation cephalosporin 1.
The 2024 JAMA guidelines similarly recommend ceftriaxone as the preferred empirical choice for patients requiring intravenous therapy, with 7-day treatment duration for β-lactams in pyelonephritis 2.
When Cefoperazone-Sulbactam Is Appropriate
Despite not being guideline-recommended first-line, cefoperazone-sulbactam has specific clinical utility:
For ESBL-Producing Organisms
Cefoperazone-sulbactam demonstrates excellent activity against ESBL-producing Enterobacteriaceae, with 95.26% susceptibility compared to 44.31% for amoxicillin-clavulanic acid 3. In regions with high ESBL prevalence (like Poland, where 32.9% of inpatient isolates showed ESBL resistance), cefoperazone-sulbactam showed 86.3% susceptibility for Klebsiella pneumoniae 4.
Clinical Efficacy Data
Recent 2025 data showed that in complicated UTIs in women, cefoperazone-sulbactam achieved faster symptom resolution, shorter defervescence time, and lower positive urine culture rates post-treatment compared to levofloxacin 5. The overall efficacy rate was 79.2% in complicated UTIs and 100% in acute uncomplicated pyelonephritis in elderly patients 6.
Practical Algorithm for Use
Use cefoperazone-sulbactam for febrile UTI when:
- Patient has risk factors for ESBL organisms (prior fluoroquinolone use, recent hospitalization, healthcare-associated infection)
- Local resistance patterns show high ESBL prevalence (>20%)
- Patient has failed first-line therapy
- Complicated UTI with systemic symptoms in regions with high resistance rates
- Culture results confirm ESBL-producing organism
Avoid as first-line when:
- Uncomplicated pyelonephritis in previously healthy patient
- No risk factors for resistant organisms
- Ceftriaxone or fluoroquinolones remain effective based on local susceptibility
Dosing and Duration
Standard dosing is 2g cefoperazone + 1g sulbactam every 12 hours intravenously 7. Treatment duration should be 7-14 days depending on clinical response and whether prostatitis can be excluded in men 1.
Critical Safety Consideration
Major caveat: Cefoperazone-sulbactam carries significant risk of coagulation disorders (8.97% incidence) 8. Concurrent vitamin K administration is essential - studies show that 2 of 6 patients not receiving vitamin K developed abnormal coagulation with one major bleeding complication, while those receiving vitamin K had no significant bleeding despite 19% having coagulation abnormalities 7.
Bottom Line
While not guideline-preferred first-line, cefoperazone-sulbactam is a reasonable and effective option for febrile UTIs when ESBL organisms are suspected or confirmed, or when first-line agents have failed. Always co-administer vitamin K and monitor coagulation parameters.